Followers | 4054 |
Posts | 152159 |
Boards Moderated | 3 |
Alias Born | 08/05/2009 |
Tuesday, December 01, 2015 7:36:20 AM
United States Patent and Trademark Office Grants Patent for Vectra(R) DA
Alert
Myriad Genetics (NASDAQ:MYGN)
Intraday Stock Chart
Today : Tuesday 1 December 2015
Click Here for more Myriad Genetics Charts.
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent No. 9,200,324. The patent, which is expected to expire in 2031, provides intellectual property protection for Crescendo Bioscience's Vectra® DA testing.
Crescendo Bioscience logo
Vectra DA is an advanced blood test for adults with rheumatoid arthritis (RA) and helps patients objectively track their disease activity over time. Vectra DA measures expression levels of twelve biomarkers that are then combined into a single score. The twelve biomarkers measured by Vectra DA are: VCAM-1, EGF, VEGF-A, IL-6, TNF-RI, MMP-1, MMP-3, YKL-40, leptin, resistin, SAA and CRP.
The recently issued patent is co-assigned to Crescendo and the Oklahoma Medical Research Foundation and is the first patent issued relating to Vectra DA. Crescendo will continue to pursue additional patent applications, which if issued, should expand the scope of intellectual property protection for Vectra DA.
"Crescendo's first patent for Vectra DA is significant because it validates the innovation required to bring to market the only objective multi-biomarker test for assessing RA disease activity," said Bernie Tobin, president, Crescendo Bioscience. "The PTO's decision comes at a critical time as we enter the golden era of personalized medicine. In order for personalized medicine to become a reality, strong intellectual property protection is essential because it provides research-based companies like Crescendo with incentives to continue to invest in research and development."
About Vectra® DA
Vectra DA is the only multi-biomarker blood test for rheumatoid arthritis (RA) disease activity that integrates the concentrations of 12 serum proteins associated with RA disease activity into a single objective score, on a scale of 1 to 100, to help physicians make more informed treatment decisions. Vectra DA testing is performed at the Crescendo Bioscience state-of-the-art CLIA (Clinical Laboratory Improvement Amendments) facility. Test results are reported to the physician 5 to 7 days from shipping of the specimen to Crescendo Bioscience. Physicians can receive test results via standard mail, by fax or via the private web portal, VectraView. For more information on Vectra DA, please visit: www.Vectra-DA.com.
About Crescendo Bioscience
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc., is a molecular diagnostics company dedicated to developing and commercializing quantitative blood tests for rheumatoid arthritis (RA) and other autoimmune diseases, located in South San Francisco, Calif. Crescendo Bioscience develops quantitative, objective, reproducible blood tests to provide rheumatologists with deeper clinical insight to help enable more effective management of patients with autoimmune and inflammatory diseases. For more information, please visit the company website at www.CrescendoBio.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G
Safe Harbor Statement
Recent MYGN News
- Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference • GlobeNewswire Inc. • 09/18/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/16/2024 06:30:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 08:11:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 08:09:19 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/11/2024 07:26:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/11/2024 02:05:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/09/2024 09:48:14 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/09/2024 06:52:57 PM
- Myriad Genetics to Host Investor Event on October 9, 2024 • GlobeNewswire Inc. • 09/05/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 11:51:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 11:38:06 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:33:41 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/03/2024 02:11:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2024 08:48:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/23/2024 08:16:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 08:38:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/19/2024 06:46:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:27:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 12:22:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:09:08 PM
- Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12% • GlobeNewswire Inc. • 08/06/2024 08:05:00 PM
- Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific • GlobeNewswire Inc. • 08/01/2024 08:05:00 PM
- Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer • GlobeNewswire Inc. • 07/31/2024 12:50:00 PM
- Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024 • GlobeNewswire Inc. • 07/30/2024 12:00:00 PM
- What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM